Literature DB >> 35264726

Schizophrenia: a disorder of broken brain bioenergetics.

Nicholas D Henkel1, Xiajoun Wu2, Sinead M O'Donovan2, Emily A Devine2, Jessica M Jiron2, Laura M Rowland3, Zoltan Sarnyai4, Amy J Ramsey5, Zhexing Wen6, Margaret K Hahn7, Robert E McCullumsmith2,8.   

Abstract

A substantial and diverse body of literature suggests that the pathophysiology of schizophrenia is related to deficits of bioenergetic function. While antipsychotics are an effective therapy for the management of positive psychotic symptoms, they are not efficacious for the complete schizophrenia symptom profile, such as the negative and cognitive symptoms. In this review, we discuss the relationship between dysfunction of various metabolic pathways across different brain regions in relation to schizophrenia. We contend that several bioenergetic subprocesses are affected across the brain and such deficits are a core feature of the illness. We provide an overview of central perturbations of insulin signaling, glycolysis, pentose-phosphate pathway, tricarboxylic acid cycle, and oxidative phosphorylation in schizophrenia. Importantly, we discuss pharmacologic and nonpharmacologic interventions that target these pathways and how such interventions may be exploited to improve the symptoms of schizophrenia.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35264726     DOI: 10.1038/s41380-022-01494-x

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   13.437


  175 in total

Review 1.  New Trends in the Treatment of Schizophrenia.

Authors:  Herbert Y Meltzer
Journal:  CNS Neurol Disord Drug Targets       Date:  2017       Impact factor: 4.388

2.  A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia.

Authors:  Mario Fioravanti; Olimpia Carlone; Barbara Vitale; Maria Elena Cinti; Linda Clare
Journal:  Neuropsychol Rev       Date:  2005-06       Impact factor: 7.444

Review 3.  Schizophrenia and increased risks of cardiovascular disease.

Authors:  Charles H Hennekens; Alissa R Hennekens; Danielle Hollar; Daniel E Casey
Journal:  Am Heart J       Date:  2005-12       Impact factor: 4.749

Review 4.  Developing treatments for cognitive deficits in schizophrenia: the challenge of translation.

Authors:  J W Young; M A Geyer
Journal:  J Psychopharmacol       Date:  2014-12-16       Impact factor: 4.153

Review 5.  Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

Authors:  Michael F Green; Keith H Nuechterlein; James M Gold; Deanna M Barch; Jonathan Cohen; Susan Essock; Wayne S Fenton; Fred Frese; Terry E Goldberg; Robert K Heaton; Richard S E Keefe; Robert S Kern; Helena Kraemer; Ellen Stover; Daniel R Weinberger; Steven Zalcman; Stephen R Marder
Journal:  Biol Psychiatry       Date:  2004-09-01       Impact factor: 13.382

6.  The Economic Burden of Schizophrenia in the United States in 2013.

Authors:  Martin Cloutier; Myrlene Sanon Aigbogun; Annie Guerin; Roy Nitulescu; Agnihotram V Ramanakumar; Siddhesh A Kamat; Michael DeLucia; Ruth Duffy; Susan N Legacy; Crystal Henderson; Clement Francois; Eric Wu
Journal:  J Clin Psychiatry       Date:  2016-06       Impact factor: 4.384

Review 7.  Schizophrenia: a concise overview of incidence, prevalence, and mortality.

Authors:  John McGrath; Sukanta Saha; David Chant; Joy Welham
Journal:  Epidemiol Rev       Date:  2008-05-14       Impact factor: 6.222

Review 8.  A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?

Authors:  Sukanta Saha; David Chant; John McGrath
Journal:  Arch Gen Psychiatry       Date:  2007-10

Review 9.  A systematic review of the prevalence of schizophrenia.

Authors:  Sukanta Saha; David Chant; Joy Welham; John McGrath
Journal:  PLoS Med       Date:  2005-05-31       Impact factor: 11.069

Review 10.  A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology.

Authors:  John McGrath; Sukanta Saha; Joy Welham; Ossama El Saadi; Clare MacCauley; David Chant
Journal:  BMC Med       Date:  2004-04-28       Impact factor: 8.775

View more
  2 in total

1.  Plasma linoelaidyl carnitine levels positively correlated with symptom improvement in olanzapine-treated first-episode drug-naïve schizophrenia.

Authors:  Xuan Wang; Meihong Xiu; Keqiang Wang; Xiuru Su; Xirong Li; Fengchun Wu
Journal:  Metabolomics       Date:  2022-07-11       Impact factor: 4.747

2.  Plasma metabolomics of schizophrenia with cognitive impairment: A pilot study.

Authors:  Yihe Jiang; Xiujia Sun; Miaowen Hu; Lei Zhang; Nan Zhao; Yifeng Shen; Shunying Yu; Jingjing Huang; Huafang Li; Wenjuan Yu
Journal:  Front Psychiatry       Date:  2022-09-28       Impact factor: 5.435

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.